GlassScriptPhysician profile
Chevone R Vent
NPI 1053578757
$489.68
in general payments reported to CMS, 2019-2025
13 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.54 · 2022: $18.47 · 2023: $86.44 · 2024: $90.97 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $122.74 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Pfizer INC. | $54.61 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $46.34 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $42.70 | 2023-2024 | Lynparza, Airsupra, Farxiga |
| Incyte Corporation | $37.00 | 2025 | Jakafi |
| Novo Nordisk INC | $31.96 | 2024-2025 | Wegovy |
| Dexcom, INC. | $30.56 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $29.70 | 2025 | Evenity, Prolia |
| Exelixis INC. | $24.44 | 2025 | Cabometyx |
| Exact Sciences Corporation | $23.85 | 2024 | Cologuard Collection Kit |
| Abbvie INC. | $18.47 | 2022 | |
| Mannkind Corporation | $14.27 | 2023 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $13.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chevone Vent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.